When more patients with known AF or atrial flutter and HTN at baseline were included, the preventive effect of SGLT2 inhibitors on AF was also reduced (β = 0.022, P = 0.003 and β = 0.020, P = 0.002, respectively). The gene discussed is SLC5A2; the disease is atrial flutter.